Zoldonrasib added to chemotherapy for metastatic pancreatic cancer with a KRAS G12D mutation
Tests zoldonrasib plus chemotherapy against placebo plus chemotherapy in metastatic pancreatic adenocarcinoma.
Key facts
- Who runs it
- Revolution Medicines, Inc.
- Where
- Atlanta, Baltimore, Boston, Chicago, Durham, East Brunswick, Gainesville, Houston, Jacksonville, Nashville, New Brunswick, New Haven, New York, Phoenix, Rochester, Tampa, and Tucson, United StatesSee the 18 sitesAlso in 4 other countries, 7 sites
- Trial code
- Registry title
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 670 people, planned
- Started
- 22 May 2026
- Expected to end
- 22 Apr 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Zoldonrasib
- Placebo
- Oxaliplatin
- Leucovorin (Calcium Folinate)
- 5-Fluorouracil
- Irinotecan
- Gemcitabine (GEM)
- Nab-paclitaxel
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic pancreatic adenocarcinoma that has a KRAS G12D mutation and who have not yet had cancer drug treatment for the spread of the disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Pancreatic adenocarcinoma confirmed by tissue or cell tests; metastatic disease diagnosed 6 weeks or less before screening; disease that can be measured on scans (RECIST v1.1)
- Earlier treatment
- No earlier systemic anticancer treatment for unresectable locally advanced or metastatic disease. No earlier systemic RAS-targeted therapy at any time.
- Biomarker or test result
- A documented KRAS G12D mutation
Main reasons for not taking part
- Earlier systemic anticancer treatment for unresectable locally advanced or metastatic disease
- Earlier systemic RAS-targeted therapy
- Other known driver mutations with approved targeted therapies
- Active or known untreated cancer spread to the brain or spinal cord
- Major surgery within 28 days before randomization
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- At least 18 years old and has provided informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed pancreatic adenocarcinoma
- Diagnosis of metastatic disease ≤ 6 weeks prior to screening
- Documented KRAS G12D mutation status
- Measurable disease per RECIST v1.1
- Adequate organ function (bone marrow, liver, kidney, coagulation)
- Able to take oral medications
Who cannot take part
- Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting
- Prior systemic RAS-targeted therapy any time prior to randomization
- Presence of other known driver mutations with approved targeted therapies
- Major surgery within 28 days prior to randomization
- Active or known history of untreated central nervous system metastatic disease
- Any conditions that may affect the ability to take or absorb study drug
- Patient is unable or unwilling to comply with protocol-required study visits or procedures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Has a test of your tumor found a change in the KRAS gene called G12D?
Where in United States
Also in 4 other countries, 7 sites
- Piedmont Cancer InstituteAtlanta, United StatesContact: AdamsTaking people
- Piedmont HealthcareAtlanta, United StatesContact: MieriTaking people
- Johns Hopkins UniversityBaltimore, United StatesContact: ApostolTaking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: LindquistTaking people
- University of Chicago Medical CenterChicago, United StatesContact: DesgardinTaking people
- Duke Cancer CenterDurham, United StatesContact: CurrierTaking people
- Astera Cancer CareEast Brunswick, United StatesContact: YaoTaking people
- University of FloridaGainesville, United StatesContact: AllegraTaking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: RossTaking people
- Mayo Clinic FloridaJacksonville, United StatesContact: BabikerTaking people
- Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: CardinTaking people
- Rutgers Cancer UniversityNew Brunswick, United StatesContact: DiOrioTaking people
- Yale UniversityNew Haven, United StatesContact: BoatengTaking people
- Columbia University Irving Medical CenterNew York, United StatesContact: ManjiTaking people
- Mayo Clinic - ArizonaPhoenix, United StatesContact: Bekaii-SaabTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: JaziehTaking people
- Moffitt Cancer CenterTampa, United StatesContact: KimTaking people
- The University of Arizona Cancer Center-North CampusTucson, United StatesContact: ZimmermanTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
The 2 groups in the trial
- Arm A: zoldonrasib + chemotherapyTreatment being tested
study drug in combination with Investigator choice chemotherapy (mFFX or GnP)
Treatment: Zoldonrasib, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), and Nab-paclitaxel
- Arm B: placebo + chemotherapyPlacebo, for comparison
placebo in combination with Investigator choice chemotherapy (mFFX or GnP)
Treatment: Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), and Nab-paclitaxel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
- Plain-language title
- Zoldonrasib added to chemotherapy for metastatic pancreatic cancer with a KRAS G12D mutationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07621718, who can take part
- Record updated
- 6 November 2026